These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 8260279)

  • 1. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators.
    Houde C; Bohn DJ; Freedom RM; Rabinovitch M
    Br Heart J; 1993 Nov; 70(5):461-8. PubMed ID: 8260279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of primary pulmonary arterial hypertension: current status].
    Solèr M
    Schweiz Med Wochenschr; 1994 Oct; 124(39):1701-7. PubMed ID: 7939536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.
    Halliday SJ; Hemnes AR; Robbins IM; Pugh ME; Zhao DX; Piana RN; Fong PP; Brittain EL
    J Heart Lung Transplant; 2015 Mar; 34(3):312-8. PubMed ID: 25577565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic impact of pulmonary vasodilators on single ventricle physiology.
    Castaldi B; Bordin G; Padalino M; Cuppini E; Vida V; Milanesi O
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29193758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the acute pulmonary vascular effects of oxygen with nitric oxide and diltiazem: implications for the long-term treatment of pulmonary arterial hypertension.
    Day RW
    Congenit Heart Dis; 2013; 8(1):71-7. PubMed ID: 22891699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.
    Rich S; Brundage BH; Levy PS
    Circulation; 1985 Jun; 71(6):1191-6. PubMed ID: 3995712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension.
    Xu QX; Yang YH; Geng J; Zhai ZG; Gong JN; Li JF; Tang X; Wang C
    Chin Med J (Engl); 2017 Feb; 130(4):382-391. PubMed ID: 28218209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute haemodynamic effects of nifedipine in patients with ventricular septal defect.
    Berisha S; Goda A; Kastrati A; Frasheri A; Popa Y
    Br Heart J; 1988 Aug; 60(2):149-55. PubMed ID: 3415874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
    Sitbon O; Humbert M; Jagot JL; Taravella O; Fartoukh M; Parent F; Herve P; Simonneau G
    Eur Respir J; 1998 Aug; 12(2):265-70. PubMed ID: 9727772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of vasodilators at rest and during exercise in young adults with cystic fibrosis and chronic cor pulmonale.
    Geggel RL; Dozor AJ; Fyler DC; Reid LM
    Am Rev Respir Dis; 1985 Apr; 131(4):531-6. PubMed ID: 3994148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the haemodynamic effects of epoprostenol (prostacyclin) and tolazoline.
    Bush A; Busst CM; Knight WB; Shinebourne EA
    Br Heart J; 1988 Aug; 60(2):141-8. PubMed ID: 3046646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effects of vasodilator therapy in primary pulmonary hypertension. Experience in 7 cases].
    Lanzarini L; Gavazzi A; Mussini A; Graziano G; Campana C; Bargiggia G; Angoli L; Aimè E; Arbustini E; Montemartini C
    G Ital Cardiol; 1990 Feb; 20(2):114-22. PubMed ID: 2328864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of escalating doses of sildenafil on hemodynamics and gas exchange in children with pulmonary hypertension and congenital cardiac defects.
    Raja SG; Danton MD; MacArthur KJ; Pollock JC
    J Cardiothorac Vasc Anesth; 2007 Apr; 21(2):203-7. PubMed ID: 17418732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasodilator therapy for primary pulmonary hypertension in children.
    Barst RJ; Maislin G; Fishman AP
    Circulation; 1999 Mar; 99(9):1197-208. PubMed ID: 10069788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilator therapy for primary pulmonary hypertension.
    McGoon MD; Vlietstra RE
    Mayo Clin Proc; 1984 Oct; 59(10):672-7. PubMed ID: 6148467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
    Hermiller JB; Bambach D; Thompson MJ; Huss P; Fontana ME; Magorien RD; Unverferth DV; Leier CV
    Ann Intern Med; 1982 Oct; 97(4):480-9. PubMed ID: 7125407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension.
    Turanlahti MI; Laitinen PO; Sarna SJ; Pesonen E
    Heart; 1998 Feb; 79(2):169-74. PubMed ID: 9538311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
    Phlippoteau C; Brenot F; Blétry O; Simmonneau G; Duroux P
    Rev Mal Respir; 1990; 7(3):249-54. PubMed ID: 2114030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute vasodilator testing following Fontan palliation: an opportunity to guide precision care?
    Day RW
    Cardiol Young; 2020 Jun; 30(6):829-833. PubMed ID: 32441233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic effects of nifedipine in primary pulmonary hypertension.
    Douglas JS
    J Am Coll Cardiol; 1983 Jul; 2(1):174-9. PubMed ID: 6853910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.